Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00238316 · ClinicalTrials.gov registry record · Phase 2
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
A Phase 2 study of Breast Cancer, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 10
- Study locations
NCT00238316: Completed Phase 2 study of Breast Cancer, sponsored by NCIC Clinical Trials Group.
NCT00238316 is a Phase 2 study of Breast Cancer that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 68 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00238316, a Phase 2 study of Breast Cancer, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 10
- Study locations
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of letrozole may stop cancer from forming or coming back in postmenopausal women who are at increased risk for breast cancer due to high breast density. PURPOSE: This randomized phase II trial is studying how well letrozole works in preventing breast cancer in postmenopausal women who are at increased risk for breast cancer due to high breast density.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG letrozole
Study Locations (10)
Ontario
- Hamilton Osteoporosis Diagnostic Services - Hamilton
- Ottawa Hospital Regional Cancer Centre - General Campus - Ottawa
- St. Catharines General Hospital at Niagara Health System - St. Catharines
- Toronto Sunnybrook Regional Cancer Centre at Sunnybrook Health Sciences Centre - Toronto
- Princess Margaret Hospital - Toronto
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
Alberta
- Tom Baker Cancer Centre - Calgary - Calgary
Nova Scotia
- Nova Scotia Cancer Centre - Halifax
Quebec
- Hotel Dieu de Montreal - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2000-12-05 |
| Est. Completion | 2009-02-10 |
| Phase | Phase 2 |
What the finished NCT00238316 record still lists
NCT00238316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00238316 lists 10 locations in 5 states (Ontario, Massachusetts, Alberta).
Frequently Asked Questions
What is clinical trial NCT00238316 about?
NCT00238316 is a clinical study titled "Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of letrozole may stop cancer from forming or coming back in postmenopausal women who are at increased risk for breast cancer due to high breast density. PURPOSE: This randomized phas...
What is the current status of trial NCT00238316?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2000-12-05. Estimated completion is 2009-02-10.
What conditions does trial NCT00238316 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00238316?
The interventions under investigation include: Placebo (OTHER), letrozole (DRUG).
Who is sponsoring clinical trial NCT00238316?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00238316 being conducted?
This trial has 10 study locations across Massachusetts, Alberta, Nova Scotia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00238316's enrollment target sits among peer trials
68 706th of 1224 higher than 509 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI